Ikena Oncology receives FDA fast track designation for novel TEAD inhibitor IK-930 to treat unresectable NF2 deficient mesothelioma

Ikena Oncology

22 June 2022 - Ikena Oncology today announced that the U.S. FDA has granted fast track designation for IK-930, the Company’s novel TEAD inhibitor targeting the Hippo signalling pathway, in patients with unresectable NF2 deficient malignant pleural mesothelioma.

IK-930 binds to TEAD transcription factors to prevent transcription of multiple genes in the Hippo pathway that are known to cause cancer progression.

Read Ikena Oncology press release 

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Dossier , Fast track